Back to discover
Disease

Acanthamoeba Keratitis

Late-stage therapeutic developmentEmerging research
MeSHAcanthamoeba Keratitis
1
Publications
6
Clinical trials
2021
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Approval: Akantior (EMA)

Regulatory2024-08-22EMA

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q3 2029.
Upcoming Milestones
Major developments
Upcoming trial readoutHigh impact
Parasitic Ulcer Treatment Trial
Results expected Q3 20292026-05-01
Major trial resultsHigh impact
Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction
Results posted2026-01-30
Clinical Milestones2View
Results posted 1
Results expected 1
Activity timeline2

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Polihexanideapproved

Approval — Akantior is indicated for the treatment of Acanthamoeba keratitis in adults and children… (2024)

Clinical trials

4 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
6
All trials
1
Active
3
Late-stage
5
Completed
Recruiting

Parasitic Ulcer Treatment Trial

Phase 3 · Recruiting · Jeremy Keenan, MD, MPH
Recently completed

Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction

Phase 3 · Completed · University of California, San Francisco

Ultrahigh-resolution Optical Coherence Tomography Imaging of the Anterior Eye Segment Structures - a Pilot Study

N/A · Completed · Medical University of Vienna

Parasitic Ulcer Treatment Trial Pilot

Phase 2 · Completed · University of California, San Francisco

Randomized, Active-Controlled, Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of 0.08% PHMB Ophthalmic Solution in Comparison With 0.02% PHMB + 0.1% Propamidine Combination Therapy in Subjects Affected by Acanthamoeba Keratitis

Phase 3 · Completed · SIFI SpA

Randomized, Double-Masked, Placebo-Controlled Multiple-Dose Phase 1 Study to Evaluate the Safety and Tolerability of Different Doses of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects

Phase 1 · Completed · SIFI SpA

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2024emaApproval — Polihexanide· Akantior is indicated for the treatment of Acanthamoeba keratitis in adults and children from 12 years of age. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Major themes2
  • Acanthamoeba Keratitis1
  • Anti-Bacterial Agents1
Leading journals1
  • Eye (London, England)1
Leading researchers5
  • Deshmukh R1
  • Dua HS1
  • Ho CS1
  • Said DG1
  • Ting DSJ1
Affiliations (unnormalised)2
  • Division of Clinical Neuroscience1
  • Queen's Medical Centre1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Infection of the cornea by an ameboid protozoan which may cause corneal ulceration leading to blindness.

Identifiers
MeSHAcanthamoeba Keratitis
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.